Login to Your Account



Amgen Wins D-Mab OK for Fractures in Cancer Patients

By Donna Young


Monday, November 22, 2010
WASHINGTON – The FDA late Thursday approved Amgen Inc.'s denosumab 120 mg as a therapy to prevent skeletal-related events (SRE) in patients with bone metastases from solid tumors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription